Psoriatic Arthritis: Overcoming the Obstacles of Early Diagnosis and Optimal Management
Ranran Yao,An-Ping Huo,Yuan Jia,Yin Su
DOI: https://doi.org/10.1111/1756-185x.15015
2024-01-01
International Journal of Rheumatic Diseases
Abstract:Psoriatic arthritis (PsA) is a chronic, inflammatory, musculoskeletal disease with high clinical heterogeneity. It is closely correlated with psoriasis (PsO), a skin condition, but not with gender.1 With the increasing attention and recognition of Chinese rheumatologists and dermatologists, the prevalence rate of PsA among Chinese patients with PsO has significantly increased to approximately 10.4%.2 However, inadequate awareness of the disease (by both physicians and patients), delay in the first visit, and definitive diagnosis in patients with PsA will likely lead to an underestimation of the prevalence.3 The clinical presentation of patients with PsA is variable, including peripheral arthritis, spondylitis, enthesitis, dactylitis, PsO, psoriatic nail disease, and extra-articular manifestations (uveitis and inflammatory bowel disease).4 Unfortunately, when PsA patients were affected by metabolic syndrome, gout, hypertension, diabetes, atherosclerosis, or cardiovascular disease, the risk of death was significantly increased, posing a significant threat to the quality of life, function, and work productivity.5-7 The Classification Criteria for Psoriatic Arthritis (CASPAR) require patients to fulfill the prerequisite of presenting with inflammatory arthritis manifestations.8 Complementarily, musculoskeletal ultrasonography is considered one of the most sensitive techniques for detecting clinical/subclinical inflammation and aiding in early clinical diagnosis.9 The diagnostic efficacy of CASPAR criteria is further enhanced when combined with ultrasound detection of synovitis, tenosynovitis, and/or enthesitis, with the specificity increasing from 84.0% to 91.4% while maintaining high sensitivity (94.5%–95.7%).10 However, the application of musculoskeletal ultrasound is still not widespread, limiting the early diagnosis of PsA. With the expansion of the biological field, the original application of traditional synthetic disease-modified anti-rheumatic drugs (DMARDs) has been supplemented by biological/targeted synthesis DMARDs (b/tsDMARDs) such as tumor necrosis factor-α inhibitor (TNF-αi), interleukin-17 inhibitor (IL-17i), interleukin-12/23 inhibitor (IL-12/23i), and Janus kinase inhibitor (JAKi), which have begun to be implemented as the first-line clinical therapies. The guidelines established by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in 2021,11 the British Society of Rheumatology in 2022,12 and the European League Against Rheumatism (EULAR) in 202313 have led to significant advances in PsA treatment. In addition, efficacy and tolerability should be evaluated regularly, and treatment should be adjusted appropriately to achieve the goals of Treat to Target (T2T). The main goals of PsA treatment are symptom control, prevention of structural damage, restoration of joint function and social activities, and improvement of health-related quality of life. Eliminating inflammation is also crucial to achieving these objectives. However, in real-world or randomized controlled trials (RCT), only about 30% of patients treated with biological DMARDs (bDMARDs) achieved the minimal disease activity (MDA) goal within 6 months.14, 15 Therefore, it is crucial to further understand the pathogenesis of PsA and how it transitions from PsO to develop more effective biologics and small-molecule drugs that target specific cytokines and signaling pathways to control PsA or prevent the transition from PsO to PsA. Compared to peripheral joint involvement in rheumatoid arthritis (RA) and axial joint involvement in ankylosing spondylitis (AS), PsA exhibits more prominent clinical and radiographic features that are asymmetric and discontinuous,16, 17 suggesting that its pathogenesis involves more than just circulating factors in the blood. Therefore, the pathogenesis of PsA is intricate and currently poorly understood, especially since the potential association between joint lesions and other domains is also unclear. The main factors recognized in the development of PsA include immune-mediated inflammation and genetic–environmental factors (Figure 1). It is well known that bone erosion and new bone formation often coexist in the same bone microenvironment in PsA patients.18 Accumulated evidence suggests that the synovium of PsA patients exhibits significant immunopathological features, indicating that the key mechanism involves the activation of immune cells (such as type 17-like CD8+ T-cell subsets,19, 20 dendritic cells, monocytes/macrophages, neutrophils, etc.) with a pro-inflammatory cytokine profile. The activation of these immune cells further triggers the activation of fibroblasts, osteoblasts, and osteoclasts, resulting in a persistent inflammatory response, enthesitis, and joint destruction.21, 22 Besides, PsA is a disease highly influenced by genetic factors. An increasing number of PsA-related genes (such as HLA,23 IL-23R,24 etc.) have been discovered, providing valuable insights into its pathogenesis and clues for early identification of PsA in PsO patients. In addition, gene–environment interactions such as smoking, mechanical trauma, mental stress, intestinal flora, and infection are potential risk factors for PsA.9, 25-27 While the etiology of PsA remains unclear, significant progress has been made in understanding the genetic, cellular, and molecular mechanisms involved in its pathogenesis. Further exploration, with the aid of high-throughput, multi-omics technologies, will provide theoretical and experimental evidence for the early clinical diagnosis and treatment of PsA. Stress, external environment, and genetic factors are important triggers for the development of PsA, which further leads to the over-activation of immune cells at the joint site of PsA patients, including CXCR3+CD8+T cells, cytotoxic T (Tc) 17 cells, tissue-resident memory (Trm) cells, and other T-cell subsets, which have been focused on recently. B cells, dendritic cells, monocytes/macrophages, and neutrophils also play essential roles. This results in the excessive production of inflammatory cytokines in the bone microenvironment, accompanied by osteoclast-mediated bone erosion, osteoblast-mediated new bone formation, and synovial fibroblast proliferation. PsA is a complex disease, and an increasing number of experts and patients recognize that PsA is not equivalent to psoriasis plus arthritis and may involve multiple domains. Ensuring timely diagnosis and implementing tailored precision therapies are crucial objectives. Consequently, a multidisciplinary approach is warranted for accurate diagnosis and effective treatment strategies. In China, the difficulties in the early identification and diagnosis of PsA are as follows3, 28: First, there is a general lack of awareness and understanding among the general public and clinical practitioners regarding PsA. Second, atypical or latent psoriasis and a vague family history of psoriasis are responsible for diagnostic difficulties. As a result, such patients are transferred between multiple departments, leading to delayed diagnosis or misdiagnosis. Third, numerous musculoskeletal manifestations must be identified with other diseases, such as RA, AS, fibromyalgia, osteoarthritis (OA), etc. Although recent research suggests that assessment of nailfold capillaries helps predict the risk of PsO progression to PsA and may also indicate disease severity,29 there is still a lack of specific biomarkers and sensitive and widely available imaging techniques for the early diagnosis of PsA. It is therefore essential to increase awareness of PsA among clinicians and patients and to further investigate relevant diagnostic and therapeutic biomarkers. The latest guidelines offer more specific guidance on effectively addressing PsA.11-13 The objective of establishing a personalized treatment strategy for PsA patients should be to achieve optimal treatment. This involves utilizing clinical expertise, following recommendations from applicable guidelines, and engaging in shared decision-making between the patient and healthcare provider. Factors such as local healthcare resources, the specific domains affected by the disease, associated conditions and comorbidities, medication efficacy, safety, patient preferences, and cost should all be considered. Furthermore, it is imperative to strengthen the cooperation between multidisciplinary departments, such as rheumatology and dermatology, gastroenterology, ophthalmology, and orthopedics. Stratified clinical and multi-omics analysis of PsA patients, biomarker discovery, and imaging development could improve prediction and understanding of PsA. Ultimately, the goal is to achieve optimal individualized treatment for PsA, adapting to the complexity of the disease within a rapidly evolving research environment. PsA, which transitions from PsO at a certain stage, is widely recognized as the mainstream view regarding its pathogenesis.30 However, some PsA develops spontaneously in patients without (PsO),31 which suggests that the transition theory may not be correct. The occurrence, development, and disease outcome of PsA may be influenced by genetic factors or other factors from the very beginning. Another critical factor limiting breakthroughs in the field of PsA is the need for suitable animal models. Currently, mouse models of PsA are mainly induced based on the IL-23/IL-17 axis.32, 33 These models also support the theory that IL-23 is a pathogenic molecule upstream in PsA pathogenesis. However, if this theory is only a part of the picture, there may be more important therapeutic factors, immune cell types, and critical targets. This limitation in research may explain why some individuals have poor treatment responses, develop drug resistance, and struggle to achieve deep remission despite the availability of multiple treatment strategies. Therefore, further explore more suitable and human-relevant animal models for PsA, which may provide a theoretical basis and treatment strategies for addressing PsA. Ranran Yao and An-Ping Huo prepared the manuscript. Yin Su and Yuan Jia designed, reviewed, and edited the manuscript. None. The study was supported by grants from the Beijing Science and Technology Planning Project (Z191100006619111 to Dr Y. Su), the National Natural Science Foundation of China (81 871 281 to Dr Y. Jia), and the National Key R&D Program of China (2022YFC3602000 to Dr Y. Jia). The authors declare they have no conflicts of interest. Data supporting the findings of this study are available from the corresponding author upon reasonable request.